KIORA PHARMACEUTICALS INC 8-K

What Happened
Kiora Pharmaceuticals, Inc. announced that on April 3, 2026 it entered into a Securities Purchase Agreement with institutional investors and closed the private placement on April 6, 2026 to raise approximately $5.0 million in gross proceeds. At closing the company issued 438,471 shares of common stock and pre‑funded warrants to purchase up to 1,527,711 shares (exercise price $0.0001). The financing also included Tranche A‑1 warrants to purchase up to 7,864,727 shares and Tranche A‑2 warrants to purchase up to 1,966,182 shares (both warrant tranches carry a $1.94 exercise price). The combined unit price was $2.5430 per common‑share unit and $2.5429 per pre‑funded‑warrant unit. If fully exercised, the warrants could generate additional gross proceeds of approximately $19.0 million.

Key Details

• Closing date: April 6, 2026; Purchase agreement dated April 3, 2026. Press release furnished April 7, 2026.
• Securities issued: 438,471 common shares; pre‑funded warrants for up to 1,527,711 shares (ex. $0.0001); Tranche A‑1 warrants for up to 7,864,727 shares (ex. $1.94); Tranche A‑2 warrants for up to 1,966,182 shares (ex. $1.94).
• Warrant terms: Tranche A‑1 exercisable immediately, expires earlier of 9 months or 30 days after a material commercial‑opportunity event; Tranche A‑2 exercisable on issuance, expires earlier of 4 years or 30 days after notice of Phase 3 enrollment completion. Pre‑funded warrants exercisable until fully exercised.
• Ownership limits and exercises: Exercise is limited to avoid beneficial ownership above 4.99% (or 9.99% if elected); excess is satisfied by issuing pre‑funded warrants. Company must file a resale registration statement within 45 days per the Registration Rights Agreement. Warrants allow cashless exercise in certain circumstances.
• No price‑reset or broad anti‑dilution protections in the warrants; only standard pro‑rata adjustments for stock splits, etc.

Why It Matters
This financing provides Kiora with near‑term cash (~$5.0M) to fund operations and reduces immediate liquidity risk. However, the issued warrants represent significant potential future dilution (up to ~19.0M in exercise proceeds if fully exercised), and the timing of potential share issuance depends on warrant exercises and registration effectiveness. The registration rights mean investors in the financing will seek the ability to resell shares once the registration statement is effective, which may increase the float. Investors should weigh the benefit of additional capital against the dilutive potential and monitor registration status and warrant exercise activity.